Lisata closes Marea deal; preliminary price: about $378M
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Lisata Therapeutics, Inc. completed its acquisition of Marea Therapeutics on September 17, 2026; the surviving wholly owned subsidiary was renamed Marea Therapeutics, LLC. The preliminary estimated purchase price was $377.8 million. A private placement of Series C Preferred Stock generated $225.0 million in gross proceeds and closed September 18, 2026.
The unaudited pro forma statements assume the transactions occurred on January 1, 2025, and show net losses of $81.003 million for the nine months ended September 30, 2026 and $60.824 million for 2025. Each Series C Preferred share is convertible into 1,000 common shares, subject to stockholder approval and beneficial ownership limitations. The pro forma figures are informational, exclude potential synergies, and rely on preliminary acquisition valuations that could change materially.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major point$225.0 million PIPE closed through a private placement of Series C Preferred Stock. 21× market cap
Negative
- None.
Filing Explained
A holder can require cash if Lisata misses timely delivery of common shares after conversion.
After stockholder approval, former Marea holders are expected to own
Holders may deliver a conversion notice at the earlier of stockholder approval or six months after initial issuance; if Lisata fails to timely deliver common shares, a holder may require cash equal to the fair value of the undelivered shares. While that cash-settlement right exists, Lisata classifies Series C as mezzanine equity because the right can be exercised after an event not solely within the company’s control.
If approval is not obtained at the stockholder meeting, Lisata must use reasonable best efforts to seek it again at least every six months until approval. Lisata says it will finalize the preliminary purchase-price allocation as soon as practicable and no later than one year after the
8-K Event Classification
Key Figures
Key Terms
PIPE financial
SAFEs financial
mezzanine equity financial
variable interest entity financial
Replacement Awards technical
In-Process Research and Development technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did LSTA raise in the PIPE?
What were LSTA's pro forma net losses?
When can LSTA's Series C Preferred Stock convert into common stock?
AI-generated analysis. How Rhea-AI works. Not financial advice.
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trade
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
The Nasdaq Capital Market
|
|
(a)
|
Financial statements of business acquired
|
|
(b)
|
Pro forma financial information
|
|
(d)
|
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
2.1(1)
|
Agreement and Plan of Merger, dated September 17, 2026, by and among Lisata Therapeutics, Inc., Mariner Merger Sub I, Inc., Mariner Merger Sub
II, LLC and Marea Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
|
|
3.1
|
Certificate of Designation of Series C Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650)
filed with the SEC on September 17, 2026).
|
|
10.1
|
Form of Marea Stockholders Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain Marea stockholders (incorporated by
reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
|
|
10.2(1)
|
Form of Securities Purchase Agreement, dated as of September 17, 2026, by and among Lisata Therapeutics, Inc. and each investor
listed on Exhibit A thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
|
|
10.3
|
Form of Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain investors signatory thereto (incorporated by reference
to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
|
|
23.1
|
Consent of Ernst & Young LLP, Independent Auditors (incorporated by reference to Exhibit 23.1 from the Registrant’s Amendment No. 1 to
Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
|
|
|
99.1
|
Press Release issued on September 17, 2026 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September
17, 2026).
|
|
|
99.2
|
Presentation made available to the Investors by Lisata Therapeutics, Inc. and Marea Therapeutics, Inc. on September 17, 2026 (incorporated by
reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
|
|
99.3
|
Audited Combined Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the year ended December 31, 2025 and 2024 and the related notes thereto (incorporated by reference to
Exhibit 99.3 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
|
|
|
99.4
|
Unaudited Condensed Combined Interim Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the six months ended June 30, 2026 and 2025 and
the related notes thereto (incorporated by reference to Exhibit 99.4 from the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
|
|
|
99.5
|
Unaudited Pro Forma Condensed Combined Financial Information of the Company as of and for the six months ended June 30, 2026 and the year ended December 31, 2025 (incorporated by reference to Exhibit 99.5 from
the Registrant’s Amendment No. 1 to Current Report on Form 8-K (File No. 001-33650) filed with the SEC on November 12, 2026).
|
|
|
99.6
|
Unaudited Pro Forma Condensed Combined Statement of Operations of the Company for the nine months ended September 30, 2026 and the year ended December 31, 2025.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
Lisata Therapeutics, Inc.
|
||
|
Date: November 19, 2026
|
By:
|
/s/ David J. Mazzo, Ph.D.
|
|
David J. Mazzo, Ph.D.
|
||
|
Chief Executive Officer
|
||
| 1. |
1,793,129 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), which represented no more than 19.9% of the outstanding shares of Common Stock
immediately prior to the Merger; and
|
| 2. |
211,365.213 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.01 per share (the “Series C Preferred Stock”).
|
| • |
The Company's historical consolidated financial statements, accompanying notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included
in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC on March 12, 2026 and amended on April 28, 2026, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed
with the SEC on November 13, 2026;
|
| • |
The historical audited financial statements of Marea (including M2 on a combined basis, as described in Note 2) as of and for the year ended December 31, 2025, and the historical
unaudited condensed financial statements of Marea for the period from January 1, 2026 through June 30, 2026, as filed with the SEC as Exhibits 99.3 and 99.4 to the Company's Current Report on Form 8-K/A filed on November 12, 2026; and
|
| • |
The Agreement and Plan of Merger, dated September 17, 2026, by and among Lisata, First Merger Sub, Second Merger Sub and Marea, as filed with the SEC as Exhibit 2.1 to the
Company's Current Report on Form 8-K filed on September 17, 2026.
|
|
|
Historical
Lisata
|
Historical
Marea
|
Transaction
Accounting
Adjustments
|
Notes
|
Combined
Pro Forma
|
||||||||||||
|
Revenue
|
$
|
170
|
$
|
-
|
$
|
-
|
$
|
170
|
|||||||||
|
Operating expenses:
|
|||||||||||||||||
|
General and administrative
|
10,430
|
11,839
|
5,347
|
AA
|
27,616
|
||||||||||||
|
Research and development
|
7,949
|
54,264
|
3,631
|
AA
|
65,844
|
||||||||||||
|
Total operating expenses
|
18,379
|
66,103
|
8,978
|
93,460
|
|||||||||||||
|
|
|||||||||||||||||
|
Loss from operations
|
(18,209
|
)
|
(66,103
|
)
|
(8,978
|
)
|
(93,290
|
)
|
|||||||||
|
|
|||||||||||||||||
|
Interest and other income
|
806
|
3,608
|
-
|
4,414
|
|||||||||||||
|
Other income (expense), net
|
(145
|
)
|
(127
|
)
|
-
|
(272
|
)
|
||||||||||
|
Total other income, net
|
661
|
3,481
|
-
|
4,142
|
|||||||||||||
|
|
|||||||||||||||||
|
Net loss before provision for income taxes
|
(17,548
|
)
|
(62,622
|
)
|
(8,978
|
)
|
(89,148
|
)
|
|||||||||
|
Benefit from income taxes
|
(962
|
)
|
-
|
(27,362
|
)
|
DD
|
(28,324
|
)
|
|||||||||
|
Net loss and comprehensive loss
|
$
|
(16,586
|
)
|
$
|
(62,622
|
)
|
$
|
18,384
|
$
|
(60,824
|
)
|
||||||
|
|
|||||||||||||||||
|
Basic and diluted earnings per share (1)
|
|||||||||||||||||
|
Net loss per share - basic and diluted
|
$
|
(1.91
|
)
|
$
|
(5.80
|
)
|
|||||||||||
|
Weighted average shares outstanding- basic and diluted
|
8,687
|
10,480
|
|||||||||||||||
|
Historical
Lisata for
the nine month
period
ended 9/30/2026
(as
reported)
|
Historical
Marea
for the
six month
period
ended
6/30/2026
|
Historical
Marea for
the period
7/1/2026
to
9/16/2026
|
Transaction
Accounting
Adjustments
|
Notes
|
Combined
Pro Forma
|
||||||||||||||||
|
Operating expenses:
|
|||||||||||||||||||||
|
General and administrative
|
$
|
11,970
|
$
|
6,846
|
$
|
7,509
|
$
|
3,077
|
BB
|
$
|
29,402
|
||||||||||
|
Research and development
|
6,994
|
46,171
|
17,771
|
1,973
|
BB
|
72,909
|
|||||||||||||||
|
Total operating expenses
|
18,964
|
53,017
|
25,280
|
5,050
|
102,311
|
||||||||||||||||
|
|
|||||||||||||||||||||
|
Loss from operations
|
(18,964
|
)
|
(53,017
|
)
|
(25,280
|
)
|
(5,050
|
)
|
(102,311
|
)
|
|||||||||||
|
|
|||||||||||||||||||||
|
Interest and other income
|
473
|
897
|
166
|
-
|
1,536
|
||||||||||||||||
|
Other income (expense), net
|
(2,127
|
)
|
(38
|
)
|
(10,924
|
)
|
10,839
|
CC
|
(2,250
|
)
|
|||||||||||
|
Total other income (loss), net
|
(1,654
|
)
|
859
|
(10,758
|
)
|
10,839
|
(714
|
)
|
|||||||||||||
|
|
|||||||||||||||||||||
|
Net loss before provision for income taxes
|
(20,618
|
)
|
(52,158
|
)
|
(36,038
|
)
|
5,789
|
(103,025
|
)
|
||||||||||||
|
Benefit from income taxes
|
(6,413
|
)
|
-
|
-
|
(15,609
|
)
|
DD
|
(22,022
|
)
|
||||||||||||
|
Net loss and comprehensive loss
|
$
|
(14,205
|
)
|
$
|
(52,158
|
)
|
$
|
(36,038
|
)
|
21,398
|
$
|
(81,003
|
)
|
||||||||
|
|
|||||||||||||||||||||
|
Basic and diluted earnings per share (1)
|
|||||||||||||||||||||
|
Net loss per share - basic and diluted
|
$
|
(1.55
|
)
|
$
|
(7.47
|
)
|
|||||||||||||||
|
Weighted average shares outstanding- basic and diluted
|
9,140
|
10,848
|
|||||||||||||||||||
|
Amount
|
||||
|
Shares of common stock issued to Marea stockholders
|
1,793,129
|
|||
|
Multiplied by the closing price per share of Common Stock on September 17, 2026 (1)
|
$
|
1.74
|
||
|
Estimated fair value of Common Stock issued
|
$
|
3,120
|
||
|
Series C Preferred Stock issued to Marea stockholders (excluding portion for Replacement Awards)
|
207,622.316
|
|||
|
Multiplied by the estimated fair value per share of Series C Preferred Stock (2)
|
$
|
1,740
|
||
|
Estimated fair value of Series C Preferred Stock issued
|
$
|
361,263
|
||
|
Estimated Replacement Awards attributable to pre-combination service (3)
|
$
|
13,413
|
||
|
Estimated purchase price
|
$
|
377,796
|
||
| 1. |
Reflects the closing price per share of Common Stock on September 17, 2026, the closing date of the Merger.
|
| 2. |
The liquidation preference on the preferred stock was assessed to be de minimis in value and therefore is economically equivalent to 1,000 shares of Common Stock.
|
| 3. |
Represents the portion of the acquisition date fair value of the Replacement Awards attributable to pre-combination service. The acquisition date fair value of the Replacement
Awards were fair valued using the black-scholes option pricing model and the Monte Carlo simulation model.
|
|
As of Closing
Date
|
||||
|
Assets:
|
||||
|
Cash and cash equivalents
|
$
|
72,919
|
||
|
Prepaid expenses and other current assets
|
3,711
|
|||
|
Other receivables
|
822
|
|||
|
Fixed assets
|
167
|
|||
|
In-process research and development (“IPR&D”) (4)
|
292,900
|
|||
|
Other assets
|
2,798
|
|||
|
Estimated total assets acquired
|
373,317
|
|||
|
Liabilities:
|
||||
|
Accounts payable
|
7,893
|
|||
|
Accrued liabilities and other current liabilities
|
13,452
|
|||
|
Other long-term liabilities
|
3,449
|
|||
|
Deferred tax liability
|
35,462
|
|||
|
Estimated total liabilities assumed
|
60,256
|
|||
|
Estimated total net assets acquired
|
$
|
313,061
|
||
|
Estimated purchase consideration
|
$
|
377,796
|
||
|
Estimated Goodwill
|
$
|
64,735
|
||
| 4. |
Represents the estimated fair value of Marea's IPR&D, including the MAR001 (including its half-life extended version, MAR005), MAR002 and MAR003 programs, which are determined
with the assistance of a third-party valuation specialist. IPR&D is recognized as an indefinite-lived intangible asset until completion or abandonment of the related research and development efforts. The assembled workforce is not
recognized separately from goodwill.
|
| AA. |
Represents incremental pro forma compensation expense for the Replacement Awards calculated using the acquisition date fair value of the Replacement Awards, attributable to
post-combination services with the Merger, for the year ended December 31, 2025 (in thousands):
|
|
General and administrative (1)
|
$
|
5,347
|
||
|
Research and development (2)
|
3,631
|
|||
|
$
|
8,978
|
|
Stock-based compensation expense for the Replacement Awards attributable to post combination services
for the year ended December 31, 2025
|
$
|
7,293
|
||
|
Historical Marea stock-based compensation recorded to general and administrative expenses for the year
ended December 31, 2025
|
(1,946
|
)
|
||
|
$
|
5,347
|
|
Stock-based compensation expense for the Replacement Awards attributable to post combination services
for the year ended December 31, 2025
|
$
|
4,977
|
||
|
Historical Marea stock-based compensation recorded to research and development expenses for the year
ended December 31, 2025
|
(1,346
|
)
|
||
|
$
|
3,631
|
| BB. |
Represents incremental pro forma compensation expense for the Replacement Awards calculated using the acquisition date fair value of the Replacement Awards, attributable to
post-combination services with the Merger, for the period from January 1, 2026 to September 16, 2026 (in thousands):
|
|
General and administrative (1)
|
$
|
3,077
|
||
|
Research and development (2)
|
1,973
|
|||
|
$
|
5,050
|
|
Stock-based compensation expense for the Replacement Awards attributable to post combination services
for the period from January 1, 2026 to September 16, 2026
|
$
|
4,369
|
||
|
Historical Marea stock-based compensation recorded to general and administrative expenses for the period
from January 1, 2026 to September 16, 2026
|
(1,292
|
)
|
||
|
$
|
3,077
|
|
Stock-based compensation expense for the Replacement Awards attributable to post combination services
for the period from January 1, 2026 to September 16, 2026
|
$
|
2,993
|
||
|
Historical Marea stock-based compensation recorded to research and development expenses for the period
from January 1, 2026 to September 16, 2026
|
(1,020
|
)
|
||
|
$
|
1,973
|
| CC. |
Represents the elimination of the $10.8 million loss on remeasurement of the SAFE liabilities included within Marea’s historical results of operations for the period from July 1,
2026 through September 16, 2026, as the SAFEs are assumed to have been issued and converted on January 1, 2025 in connection with the Transactions.
|
| DD. |
Represents additional income tax benefit recognized resulting from the partial release of a portion of the valuation allowance related to the Company’s preexisting deferred tax
assets due to the recognition of deferred income tax liabilities associated with the acquired intangible assets related to the Merger. The Company has determined that the deferred income tax liabilities recognized provide sufficient taxable
income to realize a portion of the Company’s preexisting deferred tax assets.
|
|
Nine Months Ended
September 30, 2026
|
Year Ended
December 31, 2025
|
|||||||
|
Numerator:
|
||||||||
|
Pro forma net loss attributable to common stockholders
|
$
|
(81,003
|
)
|
$
|
(60,824
|
)
|
||
|
Denominator:
|
||||||||
|
Historical weighted average shares of Lisata Common Stock outstanding
|
9,140
|
8,687
|
||||||
|
Less: weighted averages shares issued to Marea stockholders included in historical weighted average shares (1)
|
(85
|
)
|
-
|
|||||
|
Shares of common stock issued to Marea stockholders
|
1,793
|
1,793
|
||||||
|
Weighted average shares used in computing net loss per share, basic and diluted
|
10,848
|
10,480
|
||||||
|
Net loss per share, basic and diluted
|
$
|
(7.47
|
)
|
$
|
(5.80
|
)
|
||
|
As of September 30,
2026
|
As of December 31,
2025
|
|||||||
|
Series C Preferred Stock, as converted
|
362,233
|
362,233
|
||||||
|
Shares subject to Lisata options and restricted stock units
|
1,643
|
1,828
|
||||||
|
Shares subject to Lisata warrants
|
-
|
1,277
|
||||||
|
Shares subject to Lisata Replacement Options, as converted
|
22,801
|
22,801
|
||||||
|
Total
|
386,677
|
388,139
|
||||||